Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Daiichi Sankyo Company, Limited
  6. News
  7. Summary
    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Daiichi Sankyo : Top Management Presentation

07/30/2021 | 12:09am EDT

FY2021 Q1

Financial Results Presentation

DAIICHI SANKYO CO., LTD.

Hiroyuki Okuzawa

Director, Executive Officer, CFO

July 30, 2021

Forward-Looking Statements

Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo's future prospects. These forward looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are various inherent risks as well as uncertainties involved. As such, please note that actual results of Daiichi Sankyo may diverge materially from Daiichi Sankyo's outlook or the content of this material. Furthermore, there is no assurance that any forward-looking statements in this material will be realized. Regardless of the actual results or facts, Daiichi Sankyo is not obliged and does not have in its policy the duty to update the content of this material from the date of this material onward.

Some of the compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agency worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There are no guarantee that these compounds will become commercially available in indications under investigation.

Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material, but shall not be obliged to guarantee the absolute accuracy, appropriateness, completeness and feasibility, etc. of the information described in this material. Furthermore, any information regarding companies, organizations or any other matters outside the Daiichi Sankyo Group that is described within this material has been compiled or cited using publicly available information or other information, and Daiichi Sankyo has not performed in-house inspection of the accuracy, appropriateness, completeness and feasibility, etc. of such information, and does not guarantee the accuracy thereof.

The information described in this material may be changed hereafter without notice. Accordingly, this material or the information described herein should be used at your own judgment, together with any other information you may otherwise obtain.

This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States, Japan or elsewhere. This material disclosed here is for reference purposes only. Final investment decisions should be made at your own discretion.

Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information.

2

Agenda

  1. FY2021 Q1 Financial Results
  2. Business Update
  3. R&D Update
  4. Appendix

3

Overview of FY2021 Q1 Results

(Bn JPY)

FY2020 Q1

FY2021 Q1

YoY

Results

Results

Revenue

236.9

264.1

+11.4%

27.1

Cost of sales

82.2

85.2

2.9

SG&A expenses

71.8

81.2

9.4

R&D expenses

48.9

54.0

5.2

Core operating profit

34.1

43.7

+28.2%

9.6

Other revenue

0.1

2.1

2.0

Other expenses

0.0

0.0

-0.0

Operating profit

34.1

45.8

+34.1%

11.6

Profit before tax

41.4

47.1

5.7

Profit attributable to owners

31.9

35.2

+10.6%

3.4

of the Company

Currency

USD/JPY

107.62

109.49

+1.87

Rate

EUR/JPY

118.47

131.95

+13.48

As an indicator of ordinary profitability, "core operating profit" which excludes temporary gains and losses (other revenue and other expenses) from operating income is disclosed.

Gains and losses related to: sale of fixed assets, restructuring (excluding the sales of pipeline and launched products), impairment, loss compensation, reconciliation, and other non-temporary

and material gains and losses are included in the "temporary gains and losses".

4

Temporary gains and losses are excluded from results and forecast for cost of sales, SG&A expenses and R&D expenses shown in the list above.

Revenue

Increased by 27.1 Bn JPY (Increased by 20.5 Bn JPY excl. forex impact)

Positive Factors

(Bn JPY)

FY2020 Results

Negative Factors

236.9

Japan Business Unit

Japan Business

+3.1

Memary

-10.7

0.0

0.8

Lixiana

(incl. Innovative Pharmaceuticals,

Tarlige

+2.8

Generic, Vaccines, OTC)

Enhertu

+2.0

Oncology Business*1

2.7

0.0

Daiichi Sankyo Espha

+2.5

Vaccines business

-1.5

American Regent

11.9

0.0

Ezetimibe AG, Memantine AG etc.

Rotarix

Daiichi Sankyo Healthcare

+1.1

EU Specialty Business

1.7

0

Roxionin

Oncology Business*1 Unit

ASCA

+5.6

-2.2

1.7

0.0

Enhertu

Olmesartan

(Asia, South and Central America)

Enhertu, Dato-DXd*2

1.8

0.

American Regent Unit

Upfront Payment &

Injectafer

+5.2

Regulatory Milestone

6.6

GE injectables

+5.1

Forex Impact*3

EU Specialty Business Unit

FY2021 Results

264.1

+4.6

long-listed products

-3.2

Lixiana

Gain on sales of transferring

Positive Factors

Negative Factors

Enhertu, Dato-DXd*2 Upfront Payment & Regulatory Milestone

*1

Revenue for Daiichi Sankyo, Inc. and Daiichi Sankyo Europe's oncology products

Dato-DXd upfront payment

+1.5

*2

Dato-DXd: Datopotamab deruxtecan (DS-1062)

5

*3

Forex impact USD: +0.9, EUR : +3.5, ASCA: +2.2

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Daiichi Sankyo Co. Ltd. published this content on 30 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 July 2021 04:08:05 UTC.


© Publicnow 2021
All news about DAIICHI SANKYO COMPANY, LIMITED
09:07aDAIICHI SANKYO : ENHERTU® Reduced the Risk of Disease Progression or Death by 72..
BU
09/17AstraZeneca Sees Positive Results for Enhertu Trial
DJ
09/16Japanese shares edge up as FOMO keeps rally alive
RE
09/15China's biotech sector comes of age with big licensing deals, global ambition..
RE
09/07URAVAN MINERALS : Rises 20% as it Looks at Strategic Alternatives Because of Low..
MT
08/30Daiichi Sankyo Company, Limited Announces Results from the Multinational, Ran..
CI
08/20NIKKEI 225 : Declines 1% On Toyota, Pandemic Outlooks
MT
08/20Nikkei falls to 8-month low as Toyota drags peers, materials makers
RE
08/19Nikkei slides to 7-month low as Toyota drags peers, other cyclicals
RE
08/19Defence therapeutics selects the best 8 accumtm variants to optimize its adc ..
AQ
More news
Analyst Recommendations on DAIICHI SANKYO COMPANY, LIMITED
More recommendations
Financials
Sales 2022 1 003 B 9 119 M 9 119 M
Net income 2022 58 841 M 535 M 535 M
Net cash 2022 630 B 5 731 M 5 731 M
P/E ratio 2022 92,0x
Yield 2022 0,95%
Capitalization 5 375 B 48 910 M 48 855 M
EV / Sales 2022 4,73x
EV / Sales 2023 4,44x
Nbr of Employees 16 033
Free-Float 97,6%
Chart DAIICHI SANKYO COMPANY, LIMITED
Duration : Period :
Daiichi Sankyo Company, Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DAIICHI SANKYO COMPANY, LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 2 804,50 JPY
Average target price 3 526,15 JPY
Spread / Average Target 25,7%
EPS Revisions
Managers and Directors
Sunao Manabe President, CEO & Representative Director
Hiroyuki Okuzawa CFO, Director, Executive Officer & Head-Management
Ken Takeshita Global Director-Research & Development
Noritaka Uji Independent Outside Director
Tsuguya Fukui Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
DAIICHI SANKYO COMPANY, LIMITED-20.66%48 910
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604